Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelC.R. Bard ( BCR) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day down 0.6%. By the end of trading, C.R. Bard rose $1.73 (1.6%) to $111.04 on heavy volume. Throughout the day, 1,466,546 shares of C.R. Bard exchanged hands as compared to its average daily volume of 634,900 shares. The stock ranged in a price between $108.76-$112.28 after having opened the day at $109.26 as compared to the previous trading day's close of $109.31. Other companies within the Health Services industry that increased today were: Vision-Sciences Inc (DE ( VSCI), up 9.4%, USMD Holdings ( USMD), up 8.8%, Dehaier Medical Systems ( DHRM), up 6.3% and Dynatronics Corporation ( DYNT), up 6.2%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $8.5 billion and is part of the health care sector. The company has a P/E ratio of 18.6, above the S&P 500 P/E ratio of 17.7. Shares are up 11.8% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate C.R. Bard a buy, 2 analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.